Design, synthesis and evaluation of new thiazolidin-4-ones as LPA₁ receptor antagonists for breast cancer therapy

References

• Hashimoto K, Tsuda H, Koizumi F et al. Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. Ann. Oncol. 25(10), 1973–1979 (2014).
   PubMed Web of Science ®Google Scholar
• Liu S, Goldstein RH, Scepansky EM et al. Inhibition of Rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer. Res. 69(22), 8742–8751 (2009).
   PubMed Web of Science ®Google Scholar
• Gote V, Nookala AR, Bolla PK et al. Drug resistance in metastatic breast cancer: tumor targeted nanomedicine to the rescue. Int. J. Mol. Sci. 22(9), 4673 (2021).
   PubMed Web of Science ®Google Scholar
• Meduri B, Pujar GV, Durai Ananda Kumar T et al. Lysophosphatidic acid (LPA) receptor modulators: structural features and recent development. Eur. J. Med. Chem. 202;222, 113574 (2021).
   Web of Science ®Google Scholar
• Zuckerman V, Sokolov E, Swet JH et al. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells. Oncotarget 7(3), 2951 (2016).
   PubMed Web of Science ®Google Scholar
• Cui R, Cao G, Bai H et al. LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway. Cancer. Cell. Int. 19(1), 1–13 (2019).
   PubMedGoogle Scholar
• Fukushima K, Otagaki S, Takahashi K et al. Promotion of cell-invasive activity through the induction of LPA receptor-1 in pancreatic cancer cells. J. Recept. Signal Transduct. 38(4), 367–371 (2018).
   PubMed Web of Science ®Google Scholar
• Wang J, Sun Y, Qu J et al. Roles of LPA receptor signaling in breast cancer. Expert. Rev. Mol. Diagn. 16(10), 1103–1111 (2016).
   PubMed Web of Science ®Google Scholar
• Rivera-Lopez CM, Tucker AL, Lynch KR. Lysophosphatidic acid (LPA) and angiogenesis. Angiogenesis 11(3), 301–310 (2008).
   PubMed Web of Science ®Google Scholar
• Boucharaba A, Serre CM, Guglielmi J et al. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. U S A. 103(25), 9643–9648 (2006).
   PubMed Web of Science ®Google Scholar
• Novel isoxazole and thiazole compounds and use thereof as drugs. Google Patents. US20030114505A1. https://patents.google.com/patent/US20030114505A1/en
   Google Scholar
• Terakado M, Suzuki H, Hashimura K et al. Discovery of ONO-7300243 from a novel class of lysophosphatidic acid receptor 1 antagonists: from hit to lead. ACS. Med. Chem. Lett. 7(10), 913–918 (2016).
   PubMed Web of Science ®Google Scholar
• Qian Y, Hamilton M, Sidduri A et al. Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts. J. Med. Chem. 55(17), 7920–7939 (2012).
   PubMed Web of Science ®Google Scholar
• David M, Ribeiro J, Descotes F et al. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int. J. Oncol. 40(4), 1133–1141 (2012).
   PubMed Web of Science ®Google Scholar
• Bhagyalalitha M, Pavan SR, Prabhu A et al. New LPA1 receptor modulators: design, synthesis, In-silico, and anticancer studies of triazole and oxadiazole analogs. J. Mol. Struct. 1295, 136672 (2024).
   Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65(1–2), 55–63 (1983).
   PubMed Web of Science ®Google Scholar
• Prabhu A. Anti-angiogenic, apoptotic and matrix metalloproteinase inhibitory activity of Withania somnifera (ashwagandha) on lung adenocarcinoma cells. Phytomedicine. 90, 153639 (2021).
   PubMed Web of Science ®Google Scholar
• Pavan SR, Venkatesan J, Prabhu A. Anticancer activity of silver nanoparticles from the aqueous extract of Dictyota ciliolata on non-small cell lung cancer cells. J. Drug Deliv. Sci. Technol. 74, 103525 (2022).
   Web of Science ®Google Scholar
• Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2(2), 329–333 (2007).
   PubMed Web of Science ®Google Scholar
• Naik M, Brahma P, Dixit M. A cost-effective and efficient chick ex-ovo CAM assay protocol to assess angiogenesis. Methods. Protoc. 1(2), 19 (2018).
   PubMedGoogle Scholar
• Cheraghi O, Dehghan G, Mahdavi M et al. Potent anti-angiogenic and cytotoxic effect of conferone on human colorectal adenocarcinoma HT-29 cells. Phytomedicine. 23(4), 398–405 (2016).
   PubMed Web of Science ®Google Scholar
• Marshall JC, Collins JW, Nakayama J et al. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J. Natl. Cancer Inst. 104(17), 1306–1319 (2012).
   PubMedGoogle Scholar
• Wang J, Peng W, Li X et al. Towards to potential 2-cyano-pyrimidines cathepsin-K inhibitors: an in-silico design and screening research based on comprehensive application of quantitative structure–activity relationships, molecular docking and ADMET prediction. J. Mol. Struct. 1195, 914–928 (2019).
   Web of Science ®Google Scholar
• Mandal S, Kumar Br P, Alam MT et al. Novel imidazole phenoxyacetic acids as inhibitors of USP30 for neuroprotection implication via the ubiquitin-Rho-110 fluorometric assay: design, synthesis, and in-silico and biochemical assays. ACS Chem. Neurosci. 13(9), 1433–1445 (2022).
   PubMed Web of Science ®Google Scholar
• Chrencik JE, Roth CB, Terakado M et al. Crystal structure of antagonist bound human lysophosphatidic acid receptor 1. Cell. 161(7), 1633–1643 (2015).
   PubMed Web of Science ®Google Scholar
• Brooks BR, Brooks CL, Mackerell AD et al. CHARMM: the biomolecular simulation program. J. Comput. Chem. 30(10), 1545–614 (2009).
   PubMed Web of Science ®Google Scholar
• Brooks BR, Bruccoleri RE, Olafson BD et al. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4(2), 187–217 (1983).
   Web of Science ®Google Scholar
• Hess B, Kutzner C, Van Der Spoel D et al. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4(3), 435–447 (2008).
   PubMed Web of Science ®Google Scholar
• Zoete V, Cuendet MA, Grosdidier A et al. SwissParam: a fast force field generation tool for small organic molecules. J. Comput. Chem. 32(11), 2359–2368 (2011).
   PubMed Web of Science ®Google Scholar
• Darden T, York D, Pedersen L. Particle mesh Ewald: an N· log (N) method for Ewald sums in large systems. J. Chem. Phys. 98(12), 10089–10092 (1993).
   Web of Science ®Google Scholar
• Berendsen HJC, Postma JPM, van Gunsteren WF et al. Interaction models for water in relation to protein hydration. InIntermolecular forces: proceedings of the fourteenth Jerusalem symposium on quantum chemistry and biochemistry held in jerusalem, israel. In: Intermolecular Forces ( The Jerusalem Symposia on Quantum Chemistry and Biochemistry, vol 14). Pullman B ( Ed.). Springer, Dordrecht, The Netherlands, 331–342 (1981).
   Google Scholar
• Mark P, Nilsson L. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. J. Phys. Chem. 105(43), 9954–9960 (2001).
   Web of Science ®Google Scholar
• Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. J. Chem. Phys. 126(1), 014101 (2007).
   PubMed Web of Science ®Google Scholar
• Nosé S, Klein ML. Constant pressure molecular dynamics for molecular systems. Mol Phys. 50(5), 1055–76 (1983).
   Web of Science ®Google Scholar
• Mandal S, Faizan S, Raghavendra NM et al. Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications. Mol. Divers. 27(6), 2605–2631 (2022).
   PubMed Web of Science ®Google Scholar
• David M, Sahay D, Mege F et al. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers. PLOS ONE. 9(5), e97771 (2014).
   PubMed Web of Science ®Google Scholar
• Jagodzinski TS, Wesolowska A, Sosnicki JG. Reactions of secondary beta-ketothioamides with ethyl bromoacetate and ethyl 2-bromopropionate. The synthesis of N-substituted 2-acylmethylidene-1, 3-thiazolidin-4-ones. Pol. J. Chem. 74(8), 1101–1114 (2000).
   Google Scholar
• De Monte C, Carradori S, Chimenti P et al. New insights into the biological properties of Crocus sativus L.: chemical modifications, human monoamine oxidases inhibition and molecular modeling studies. Eur. J. Med. Chem. 82, 164–171 (2014).
   PubMed Web of Science ®Google Scholar
• Tatar E, Küçükgüzel İ, De Clercq E et al. Synthesis, characterization and screening of antimicrobial, antituberculosis, antiviral and anticancer activity of novel 1,3-thiazolidine-4-ones derived from 1-[2-(benzoylamino)-4-(methylthio)butyryl]-4-alkyl/arylalkyl thiosemicarbazides. Gen. Pap. Ark. 14, 191–210 (2008).
   Google Scholar